-
Something wrong with this record ?
Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: A double-blind randomized pilot study
J. Krhut, M. Navratilova, R. Sykora, M. Jurakova, M. Gärtner, D. Mika, L. Pavliska, P. Zvara,
Language English Country England, Great Britain
Document type Comparative Study, Journal Article, Randomized Controlled Trial
- MeSH
- Administration, Intravesical MeSH
- Botulinum Toxins, Type A administration & dosage MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Urinary Bladder, Overactive drug therapy MeSH
- Acetylcholine Release Inhibitors administration & dosage MeSH
- Middle Aged MeSH
- Humans MeSH
- Drug Carriers MeSH
- Hydrogel, Polyethylene Glycol Dimethacrylate MeSH
- Pilot Projects MeSH
- Prospective Studies MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
OBJECTIVE: It was hypothesized that increasing the time for which onabotulinum toxin A (OnabotA) is exposed to the urothelium following intravesical instillation will augment its effect. TC-3 is an inert heat-sensitive hydrogel, which creates an intravesical bulk providing a slow release of the embedded drug after instillation. The aim of this study was to evaluate the effect of OnabotA, embedded in inert TC-3 hydrogel, in patients with idiopathic overactive bladder (OAB). METHODS: In total, 39 female patients (age 30-65, average 53.8 years) with OAB symptoms were randomized for the study into four groups, each receiving 50 ml of the following intravesical instillations: Group A, 0.9% NaCl (placebo, n = 11); Group B, TC-3 gel + 200 U OnabotA (n = 9); Group C, TC-3 gel + 200 U OnabotA + dimethyl sulfoxide (DMSO) (n = 10); and Group D, DMSO (n = 9). The parameters were compared before and 1 month after treatment. RESULTS: When comparing parameters using conventional statistical methods (Kruskal-Wallis test), no statistically significant changes were observed within the groups. Comparison of the medians using an analysis based on the mathematical gnostics showed the superiority of the method used in Group B over the other groups in the following parameters: number of urgency grade 3 + 4 episodes/72 h, number of leakage episodes/72 h, Overactive Bladder Questionnaire total score and Patient Perception of Bladder Condition total score. Group D showed its superiority over the other groups in respect to the number of nocturia episodes/72 h. CONCLUSIONS: The results indicate that intravesical instillation of OnabotA, embedded in TC-3 gel, could become an alternative to intramural injection for a well-selected subgroup of patients.
b Department of Obstetrics and Gynecology University Hospital Ostrava Czech Republic
c Department for Science and Research University Hospital Ostrava Czech Republic
Department of Surgical Studies Ostrava University Ostrava Czech Republic
Department of Urology University Hospital Ostrava Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17024042
- 003
- CZ-PrNML
- 005
- 20171103145102.0
- 007
- ta
- 008
- 170720s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/21681805.2015.1121406 $2 doi
- 035 __
- $a (PubMed)27111192
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Krhut, Jan $u a Department of Urology , University Hospital , Ostrava , Czech Republic ;
- 245 10
- $a Intravesical instillation of onabotulinum toxin A embedded in inert hydrogel in the treatment of idiopathic overactive bladder: A double-blind randomized pilot study / $c J. Krhut, M. Navratilova, R. Sykora, M. Jurakova, M. Gärtner, D. Mika, L. Pavliska, P. Zvara,
- 520 9_
- $a OBJECTIVE: It was hypothesized that increasing the time for which onabotulinum toxin A (OnabotA) is exposed to the urothelium following intravesical instillation will augment its effect. TC-3 is an inert heat-sensitive hydrogel, which creates an intravesical bulk providing a slow release of the embedded drug after instillation. The aim of this study was to evaluate the effect of OnabotA, embedded in inert TC-3 hydrogel, in patients with idiopathic overactive bladder (OAB). METHODS: In total, 39 female patients (age 30-65, average 53.8 years) with OAB symptoms were randomized for the study into four groups, each receiving 50 ml of the following intravesical instillations: Group A, 0.9% NaCl (placebo, n = 11); Group B, TC-3 gel + 200 U OnabotA (n = 9); Group C, TC-3 gel + 200 U OnabotA + dimethyl sulfoxide (DMSO) (n = 10); and Group D, DMSO (n = 9). The parameters were compared before and 1 month after treatment. RESULTS: When comparing parameters using conventional statistical methods (Kruskal-Wallis test), no statistically significant changes were observed within the groups. Comparison of the medians using an analysis based on the mathematical gnostics showed the superiority of the method used in Group B over the other groups in the following parameters: number of urgency grade 3 + 4 episodes/72 h, number of leakage episodes/72 h, Overactive Bladder Questionnaire total score and Patient Perception of Bladder Condition total score. Group D showed its superiority over the other groups in respect to the number of nocturia episodes/72 h. CONCLUSIONS: The results indicate that intravesical instillation of OnabotA, embedded in TC-3 gel, could become an alternative to intramural injection for a well-selected subgroup of patients.
- 650 _2
- $a inhibitory uvolňování acetylcholinu $x aplikace a dávkování $7 D065087
- 650 _2
- $a aplikace intravezikální $7 D000283
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a botulotoxiny typu A $x aplikace a dávkování $7 D019274
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a nosiče léků $7 D004337
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a PEG-DMA hydrogel $7 D020136
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a hyperaktivní močový měchýř $x farmakoterapie $7 D053201
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Navratilova, Marie $u b Department of Obstetrics and Gynecology , University Hospital , Ostrava , Czech Republic ;
- 700 1_
- $a Sykora, Radek $u a Department of Urology , University Hospital , Ostrava , Czech Republic ;
- 700 1_
- $a Jurakova, Michaela $u b Department of Obstetrics and Gynecology , University Hospital , Ostrava , Czech Republic ;
- 700 1_
- $a Gärtner, Marcel $u b Department of Obstetrics and Gynecology , University Hospital , Ostrava , Czech Republic ;
- 700 1_
- $a Mika, David $u a Department of Urology , University Hospital , Ostrava , Czech Republic ;
- 700 1_
- $a Pavliska, Lubomir $u c Department for Science and Research , University Hospital , Ostrava , Czech Republic ;
- 700 1_
- $a Zvara, Peter $u d Department of Surgical Studies , Ostrava University , Ostrava , Czech Republic.
- 773 0_
- $w MED00193240 $t Scandinavian journal of urology $x 2168-1805 $g Roč. 50, č. 3 (2016), s. 200-5
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27111192 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20171103145157 $b ABA008
- 999 __
- $a ok $b bmc $g 1239723 $s 984955
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 50 $c 3 $d 200-5 $e 20160112 $i 2168-1805 $m Scandinavian journal of urology $n Scand J Urol $x MED00193240
- LZP __
- $a Pubmed-20170720
